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Background and Objective: Treatment of peripheral neuropathic pain (PNP) remains 
a challenge. In the absence of clear predictors of response, clinical decision-making involves trial 
and error. While many classes of pharmacological agent are used and have shown efficacy, one of 
the most commonly used first-line treatments is pregabalin. However, in the 60% of PNP cases in 
which the pain is localized, a local treatment may be more suitable. This article will summarize the 
evidence for the relative effectiveness and tolerability of the capsaicin 179 mg patch and pregabalin 
in the treatment of PNP and highlight the expert opinion of the authors based on their own clinical 
experiences.
Results: When compared in a head-to-head trial in patients with PNP, capsaicin 179 mg 
patch provided non-inferior pain relief compared with an optimized dose of pregabalin, as 
well as a reduction in dynamic mechanical allodynia, faster onset of action, fewer systemic 
side effects, and greater treatment satisfaction. Adverse events associated with capsaicin 
patch are mainly application site reactions, compared with systemic and central nervous 
system effects with pregabalin. Studies indicate that capsaicin 179 mg patch is associated 
with a lower burden of therapy than pregabalin in terms of improved tolerability, lack of 
a daily pill burden, lack of drug–drug interactions, and increased regimen flexibility.
Conclusion: In localized neuropathic pain, evidence supports a pragmatic approach of using 
a local treatment before considering a systemic treatment. For treatment selection, the patient 
profile (eg, concomitant medication use, age) and the treatments’ efficacy and tolerability 
profiles should be considered.
Keywords: capsaicin, pregabalin, peripheral neuropathic pain, polyneuropathy, pain
Plain Language Summary
Peripheral neuropathic pain (PNP) is pain caused by damage or disease of the peripheral somato-
sensory nervous system. In localized PNP, the pain can be located to a well-defined area of the body. 
Control of PNP is often challenging, as many patients' PNP does not respond to oral therapies. This 
expert opinion highlights the relevance of a local therapy, capsaicin 179 mg patch, for the treatment 
of localized PNP and shows that this treatment compares favorably with pregabalin, a well- 
established oral treatment. This expert opinion is based on analyses of both indirect (meta-analysis) 
and direct head-to-head comparisons between systemic and local treatments. In a randomized trial, 
capsaicin 179 mg patch offered comparable pain relief to pregabalin, with a faster onset of pain 
relief, fewer systemic side effects, a reduced burden of treatment, and a higher reported patient 
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satisfaction. Capsaicin 179 mg patch is not associated with a daily pill 
burden and is unlikely to have drug–drug interactions, so it is appro-
priate for use in combination therapy. Patients who receive capsaicin 
179 mg patch early are more likely to respond than those who receive 
it later. For localized PNP, it is logical to start with a local therapy such 
as capsaicin 179 mg patch before moving to an oral therapy if the local 
therapy does not work. Pregabalin is a more suitable option for facial 
pain or central neuropathic pain. This expert opinion lends support to 
recently published guidelines proposing that topical treatments should 
be considered first-line therapy of localized PNP.
Introduction
Pain control in patients with peripheral neuropathic pain 
(PNP) continues to be a challenge, with many patients 
receiving unsatisfactory treatment.1 The efficacy of many 
currently available medications is unsatisfactory owing to 
their limited effect size and the low responder rate 
(<50%).2 After diagnosis of PNP, a treatment focusing 
on the underlying disease could be a first step (eg glucose 
control for painful diabetic peripheral neuropathy [DPN] 
or interruption of chemotherapy when chemotherapy- 
induced neuropathy occurs), although this does not often 
lead to a successful reversal of the neuropathic pain.3,4 
PNP is difficult to treat and often does not respond to 
conventional pain therapies because of the heterogeneity 
and complexity of the mechanisms underlying peripheral 
pain conditions, as well as the co-existence of psycholo-
gical and emotional aspects of chronic pain.
Treatment of pain requires a multimodal and individua-
lized approach. In the absence of clear predictors of treatment 
response, a stepwise approach is taken to identify which drugs 
or drug combinations offer the greatest pain relief with the 
fewest adverse effects.5,6 Pharmacotherapy is typically the first 
step and treatment classes often trialed include antidepressants 
(ie tricyclic antidepressants or selective serotonin and norepi-
nephrine reuptake inhibitors [SSRIs/SNRIs]), antiarrhythmic 
medications, alpha-2-delta subunit ligands (gabapentin and 
pregabalin), N-methyl-D-aspartate (NMDA) receptor antago-
nists, sodium channel inhibitors, and synthetic opioids.1,7 
Pregabalin (Lyrica®; Pfizer Inc., New York, NY, USA) is an 
orally administered calcium channel alpha-2-delta subunit 
ligand. It was one of the first pharmacotherapies introduced 
for the treatment of PNP (in 2004) and is approved in the USA 
and Europe for the treatment of pain from DPN and post- 
herpetic neuralgia (PHN) in adults.8 Pregabalin was developed 
in follow-up to gabapentin.9 While both have shown efficacy 
in neuropathic pain disorders, pregabalin has some pharmaco-
logical advantages, including more rapid absorption, linear 
pharmacokinetics, and greater bioavailability (≥90%) 
compared with gabapentin.9 It is approximately 2.5-times 
more potent than gabapentin based on plasma concentrations. 
In a study from Sweden, the first prescription in 2220 patients 
with neuropathy was pregabalin in 25% of patients, gabapen-
tin in 29%, and amitriptyline in 36%.10 Nevertheless, a recent 
Cochrane review concluded that “some people will derive 
substantial benefit with pregabalin; more will have moderate 
benefit, but many will have no benefit or will discontinue 
treatment”.11
In approximately 60% of cases, PNP is localized, 
affecting a specific and limited area of the body.3 In the 
case of localized PNP, it is prudent to consider a local 
treatment such as a lidocaine 5% patch or capsaicin.12
The aim of this article is to summarize the relative effec-
tiveness and tolerability of the capsaicin 179 mg (also known 
as capsaicin 8%) patch compared with pregabalin in the 
treatment of PNP conditions, and to consider the place of 
each in clinical practice. Capsaicin 179 mg cutaneous patch 
(Qutenza®; Grünenthal GmbH, Aachen, Germany) delivers 
a high concentration (8%) of synthetic capsaicin, a highly 
selective agonist of the transient receptor potential vanilloid- 
1 (TRPV1). It is approved in Europe, alone or in combina-
tion, for the treatment of PNP in adults and in the USA for the 
treatment of PNP associated with PHN.13,14
Summary of Guideline 
Recommendations
Table 1 summarizes the current guideline and consensus 
recommendations for the management of PNP. The first 
attempt to develop a specific and standardized approach to 
the diagnosis and treatment of localized PNP was made in 
2015. An international group of pain specialists convened 
to generate an expert consensus on a treatment algorithm 
for localized PNP treatment, intended for use in the pri-
mary care and other non-specialist settings. This group 
agreed that first-line treatment should begin with 
a topical analgesic agent, owing to better benefit:risk ratios 
compared with systemic medications.3 This stance has 
been corroborated by national expert consensus groups in 
France and Spain.15,16
In addition, a recent review of the literature to evaluate 
the evidence supporting the use of topical therapies for 
PNP is aligned with the expert consensus and indicates 
that first-line use of topical therapies may be particularly 
beneficial in those for which safety, tolerability, and com-
pliance are a concern, and in those who are frail or 
elderly.17 This review also points out, however, that it is 
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Table 1 Summary of Key Guideline and Consensus Recommendations for Pharmacotherapy in Neuropathic Pain
Group/Author, year Methodology Condition(s) Summary Recommendations
European Federation of 
Neurological Societies (EFNS) 
Task Force, 20107
Literature review of RCTs since 2005, identified 
using the Cochrane Database and MEDLINE 
(lower class studies considered only when no 
RCTs available)
PHN ● Level A rating: capsaicin 179 mg patcha; gabapen-
tin; gabapentin ER; lidocaine plasters, opioids; 
pregabalin, TCAs
● First line: gabapentin; pregabalin; TCAs; lidocaine 
plasters
● Second line: capsaicin; opioids
Neuropathic Pain Special Interest 
Group (NeuPSIG) of the 
International Association for the 
Study of Pain, 20154
Systematic review and meta-analysis of 
randomized, double-blind studies of oral and 
topical pharmacotherapy for neuropathic pain, 
with recommendations based on GRADE56,57
All 
neuropathic 
pain, except 
trigeminal 
neuralgia
● First line: gabapentin; gabapentin ER/enacarbil; preg-
abalin; SNRIs (duloxetine/venlafaxine); TCAs
● Second line: capsaicin 179 mg patches (PNP 
only); lidocaine patches (PNP only); tramadol
● Third line: botulinum toxin type A; strong opioids
Allegri et al, 20163 Advisory board of pain specialists convened to 
develop a treatment guidance algorithm
Localized 
neuropathic 
pain
● First line: topical treatment, ie lidocaine plasters 
(for PHN) or capsaicin patches
● Second and third lines: systemic medication (per 
first-line recommendations of the 2015 NeuPSIG 
guidelines)4
● If no response after second systemic medication, 
refer to pain specialist
Deng et al, 201658 Systematic review of 16 published clinical practice 
guidelines, assessed using the AGREE-II 
instrument59
All 
neuropathic 
pain
● First/second line: anticonvulsants (gabapentin/ 
pregabalin), low-dose TCAs; SNRIs (duloxetine/ 
venlafaxine); topical lidocaine
● Second line: opioid analgesics
● Third line: opioid analgesics; anticonvulsants (car-
bamazepine, lamotrigine, oxcarbazepine); SSRIs 
(citalopram, paroxetine); mexiletine; NMDA 
receptor antagonists (dextromethorphan, mem-
antine); topical capsaicin
● Fourth line: cannabinoids; SSRIs (citalopram, par-
oxetine); anticonvulsants (carbamazepine, lamo-
trigine, clonidine); mexiletine; methadone
NICE, 201718 Committee review of the literature, economic 
analysis, lay member consultations
All 
neuropathic 
pain, except 
trigeminal 
neuralgia
● Offer a choice of amitriptyline, duloxetine, gaba-
pentin, or pregabalin as initial treatment for 
neuropathic pain
● If the initial treatment is not effective or is not 
tolerated, offer one of the remaining three drugs, 
and consider switching again if the second and 
third drugs tried are also not effective or not 
tolerated
● Consider tramadol only if acute rescue therapy is 
needed
● Consider capsaicin cream for people with loca-
lized neuropathic pain who wish to avoid, or 
who cannot tolerate, oral treatments
● Do not start the following to treat neuropathic 
pain in non-specialist settings, unless advised by 
a specialist to do so: cannabis sativa extract; 
capsaicin patch; lacosamide; lamotrigine; levetir-
acetam; morphine; oxcarbazepine; topiramate; 
long-term tramadol; venlafaxine
Note: aCapsaicin patch not available at the time of guideline development. 
Abbreviations: AGREE-II, Appraisal of Guidelines Research and Evaluation II; ER, extended release; GRADE, Grading of Recommendations Assessment, Development, and 
Evaluation; NICE, National Institute for Health and Care Excellence; NMDA, N-methyl-D-aspartate; PHN, post-herpetic neuralgia; PNP, peripheral neuropathic pain; RCT, 
randomized controlled trial; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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important to take into account the practical aspects of each 
therapy, highlighting the need for the capsaicin 179 mg 
patch to be applied by a healthcare professional (HCP). 
Similarly, the UK’s National Institute for Health and Care 
Excellence guideline, which is focused on non-specialist 
settings, recommends that the capsaicin patch should be 
initiated in non-specialist settings only on the advice of 
a pain specialist.18
Modes of Action and 
Pharmacodynamics of Capsaicin 
179 mg Patch and Pregabalin
The active ingredient in the capsaicin 179 mg patch is 
chemically synthesized capsaicin, which is absorbed 
into the epidermal and dermal layers of the skin. It is 
applied for 30 minutes to the feet (eg in human immu-
nodeficiency virus-associated neuropathy [HIV-AN], 
painful DPN) or 60 minutes to other locations (eg the 
trunk in PHN).14 Capsaicin is a potent and highly 
selective exogenous agonist of the TRPV1 channel, 
a transmembrane receptor–ion channel complex distrib-
uted throughout the central nervous system (CNS) and 
peripheral nervous system.13,19–21 TRPV1 is preferen-
tially expressed on sensory (nociceptive) nerve fibers 
and is important in pain perception. When capsaicin 
comes into contact with these nociceptors, the initial 
excitation of primary sensory TRPV1-expressing neu-
rons is experienced as a warming, burning, or stinging 
sensation with hyperalgesia.20 With continued expo-
sure, the peripheral nociceptors become less sensitive, 
leading to the “defunctionalization” and degeneration 
of nociceptors, causing them to recede from the epi-
dermis (Figure 1).13,19,22,23 In addition, secondary 
pharmacodynamic mechanisms in response to high 
doses of capsaicin have been implicated in the persis-
tent effects of capsaicin on nociceptors, including the 
defunctionalization of mitochondria due to calcium 
overload leading to nerve terminal necrosis.19,20
The mechanism of action of pregabalin is not com-
pletely understood, but it is an antagonist of voltage- 
gated calcium ion channels and is thought to bind to 
the alpha-2-delta subunit.24 This action is thought to 
reduce the release of several neurotransmitters, includ-
ing glutamate, norepinephrine, and substance P, redu-
cing neuronal excitability and alleviating allodynia and 
hyperalgesia.24,25 Pregabalin is administered orally and 
is rapidly absorbed from the intestines, with ~90% 
bioavailability.26 It is excreted almost exclusively via 
the kidneys.26 It is also known to be able to cross the 
blood–brain barrier and enter the CNS.27
Figure 1 Mechanism of action of capsaicin in treatment of localized peripheral neuropathic pain. Activation of transient receptor potential vanilloid-1 (TRPV1) by capsaicin 
results in sensory neuronal depolarization, and can induce local sensitization to activation by heat, acidosis, and endogenous agonists. Topical exposure to capsaicin leads to 
the sensations of heat, burning, stinging, or itching. High concentrations of capsaicin or repeated applications can produce a persistent local effect on cutaneous nociceptors, 
which is best described as “defunctionalization” and constituted by reduced spontaneous activity and a loss of responsiveness to a wide range of sensory stimuli. . 
Reproduced from Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentrationcapsaicin 8% patch. 
Br J Anaesth. 2011;107(4):490–502, Copyright 2011, with permission from Elsevier.19
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Clinical Comparisons Between 
Capsaicin 179 mg Patch and 
Pregabalin
To our knowledge, only one head-to-head comparative 
trial in patients with PNP has been completed to date 
and is therefore described here in more detail. 
ELEVATE, a Phase IV, 8-week, multicenter, open-label, 
randomized, non-inferiority study in 568 patients with 
PNP, was the first clinical trial to compare the capsaicin 
179 mg patch with pregabalin.28 The capsaicin 179 mg 
patch offered non-inferior pain relief compared with an 
optimized dose of pregabalin, as measured by the propor-
tion of patients in each arm who achieved ≥30% decrease 
in the ‘average pain for the past 24 hours’ Numerical Pain 
Rating Scale (NPRS) score by week 8.28 The capsaicin 
179 mg patch also demonstrated a faster onset of action 
(median time to onset was 7.5 days vs 36.0 days with 
pregabalin [p<0.001]) and was associated with fewer sys-
temic side effects and greater treatment satisfaction. 
Treatment-emergent adverse events (TEAEs) with the cap-
saicin 179 mg patch were mainly application site reactions 
versus CNS effects with pregabalin.
The ELEVATE study also demonstrated superiority of 
the capsaicin 179 mg patch over pregabalin in terms of 
reducing the intensity and area of dynamic mechanical 
allodynia (DMA).29 From baseline to week 8, the mean 
change in intensity of DMA was –2.98 (95% confidence 
interval [CI] –3.36, –2.60; p<0.0001) with the capsaicin 
patch and –2.35 (95% CI –2.76, –1.93; p<0.0001) with 
pregabalin, with an estimated between-arm difference of – 
0.63 (95% CI –1.04, –0.23; p=0.002). The mean change in 
the area of DMA was –72.6 cm2 (95% CI –44.7, –100.6; 
p<0.0001) with the capsaicin patch and –33.1 cm2 (95% 
CI –2.7, –63.6; p=0.033) with pregabalin, with an esti-
mated between-arm difference of –39.5 cm2 (95% CI – 
69.1, –10.0; p=0.009). In addition, the capsaicin patch was 
associated with a greater proportion of patients experien-
cing complete disappearance of DMA by week 8 (24.1% 
vs 12.3% with pregabalin; p=0.001).
The capsaicin 179 mg patch was compared with various 
oral medications, including pregabalin, for the treatment of 
DPN in a systematic review and network meta-analysis.30 
The capsaicin 179 mg patch was shown to be significantly 
more effective than placebo for ≥30% pain reduction (odds 
ratio [OR] 2.28 [95% CI 1.19–4.03]) and numerically better 
than pregabalin (OR 1.83 [95% CI 0.91–3.34]).
Tolerability Considerations
The differences in the tolerability profiles of the capsaicin 
179 mg patch and pregabalin are based on their differing 
modes of administration. Pregabalin is considered to be 
generally well tolerated for an oral agent, with benign 
CNS and systemic effects, few unexpected adverse effects, 
and no major drug interactions.26 The most common 
(≥10%) CNS and systemic side effects associated with 
pregabalin are dizziness, somnolence/sedation, peripheral 
edema, dry mouth, and weight gain.26,31 With the capsai-
cin 179 mg patch, the active agent is delivered directly to 
the site of pain, targeting the specific area affected and 
thus avoiding the systemic side effects associated with oral 
therapies. The typical side effects of the patch are burning 
and redness at the application site; these are transient and 
usually disappear without treatment.13
The network meta-analysis mentioned above also ana-
lyzed capsaicin 179 mg patch and oral agents in terms of 
tolerability.30 The capsaicin 179 mg patch could be 
included only for the analysis on headache as it is not 
associated with the other common systemic side effects of 
the other oral agents studied. However, no significant 
differences in the risk of headache were observed with 
any treatment versus placebo. Pregabalin, on the other 
hand, was associated with a significantly increased risk 
of somnolence (OR 4.14 [95% CI 3.00–5.60]) and dizzi-
ness (OR 4.63 [95% CI 3.44–6.16]), and numerically 
increased risk of nausea, diarrhea, constipation, headache, 
and fatigue, compared with placebo. Overall, this network 
meta-analysis suggests that the capsaicin 179 mg patch 
offers comparable efficacy to the oral agents in patients 
with DPN, but provides an improved tolerability profile.
Recently, a review and meta-analysis of Phase III ran-
domized, placebo-controlled trials of pregabalin were con-
ducted to assess the benefits and harms of pregabalin.31 
The rationale for the analysis was based on increasing 
evidence of pregabalin’s potential for abuse and reports 
of increased mortality, leading the UK government to 
reclassify the drug as a class C controlled substance.32 
While pregabalin was associated with significant benefits 
on pain reduction and sleep interference, it was also asso-
ciated with a significant increase in the risk of adverse 
events (AEs) compared with placebo (relative risk 1.33 
[95% CI 1.23–1.44]; p<0.00001), translating into an abso-
lute effect of 145 more AEs per 1000 patients treated with 
pregabalin.31 Although 23 of the 28 studies included in the 
meta-analysis examined the effectiveness of pregabalin for 
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the treatment of PNP, there are still insufficient good- 
quality randomized controlled trials of pregabalin in 
PNP.31
The Capsaicin 179 mg Patch is 
Associated with a Lower Burden of 
Therapy
The differing modes of administration between the capsai-
cin 179 mg patch and pregabalin also influence the overall 
burden of therapy. In a study designed to validate a novel 
standard methodology to evaluate treatment safety, the 
BURDEN OF THERAPY™© (BOTh™©) methodology 
was applied to the ELEVATE study results.33 BOTh has 
been developed to quantify and assess the severity of 
TEAEs using patient-level safety data on each day of 
a study, rather than over the entire study period. The aim 
is to provide improved information on the tolerability and 
safety of a given drug.
In ELEVATE, patients receiving the capsaicin 179 mg 
patch had a greater incidence of TEAEs than those receiv-
ing pregabalin (74.5% vs 63.9%, respectively).33 
However, when assessed using BOTh, a different picture 
emerged: more TEAEs were experienced for more days 
Figure 2 BURDEN OF THERAPY™© in a peripheral neuropathic pain study. TEAE, treatment-emergent adverse event; TRPV1, transient receptor potential vanilloid-1.  
Reproduced from Abdulahad AK, Snijder RJ, Panni MK, Riaz FK, Karas AJ. A novelstandard to evaluate the impact of therapeutic agents on patientsafety – the BURDEN OF 
THERAPY™©. Contemp Clin Trials Commun. 2016;4:186–191, Copyright 2016, with permission from Elsevier.33
Huygen et al                                                                                                                                                          Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                              
Journal of Pain Research 2020:13 2590
 
Jo
ur
na
l o
f P
ai
n 
R
es
ea
rc
h 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
21
3.
12
7.
84
.2
07
 o
n 
13
-N
ov
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
with pregabalin compared with the capsaicin 179 mg 
patch. It is clear from Figure 2 that there was an initial 
peak followed by a rapid decline in the number and inci-
dence of TEAEs for patients treated with the capsaicin 
179 mg patch; these were primarily transient application 
site reactions (~3 days following application). After day 4, 
<15% of those in the capsaicin 179 mg patch group 
reported TEAEs for the remainder of the study. However, 
TEAEs with pregabalin increased during dose titration and 
generally persisted to the end of the study. The overall 
burden estimate was 23.5 for the capsaicin 179 mg patch 
and 61.2 for pregabalin (p<0.0001). Figure 2 also allows 
comparison of the severity of the TEAEs between the 
treatment arms, with more weighted moderate and severe 
TEAEs in the pregabalin arm.
This BOTh study also examined the safety burden in 
the context of the median time to treatment response 
(defined as the first of three consecutive days in which 
the patient reported a ≥30% reduction in average daily 
pain score) in both arms during ELEVATE.33 Patients 
receiving the capsaicin 179 mg patch achieved this treat-
ment response in a median of 7.5 days, convergent with 
the period in which transient application site reactions 
were reported, while those receiving pregabalin achieved 
this treatment response in a median of 36 days, coinciding 
with dose titration and the increase in reported drug- 
related TEAEs.
These findings demonstrate that the capsaicin 179 mg 
patch is associated with a lower burden of therapy than 
pregabalin in terms of tolerability and the incidence of 
AEs, suggesting it may be an attractive option for doctors 
and patients. This was reflected in ELEVATE with patients 
reporting significantly greater treatment satisfaction with 
capsaicin 179 mg patch compared with pregabalin, and 
a greater proportion of patients willing to continue treat-
ment with the capsaicin 179 mg patch, as assessed at the 
week 8 visit.28 In other studies, capsaicin 179 mg was 
associated with improvements from baseline in quality of 
life (QoL) and patient satisfaction, as measured by the 
EuroQol 5-dimensions questionnaire index score and 
Patient Global Impression of Change (PGIC).34,35 Few 
studies have assessed the effect of pregabalin on QoL 
outcomes, and those that have report mixed results or no 
significant difference versus placebo. Thus, there is insuf-
ficient evidence to make definitive statements on pregaba-
lin’s effects on QoL.31
The capsaicin 179 mg patch is not associated with 
a daily pill burden, and adherence to treatment is 
determined by whether patients complete the intended 
application time. In phase III clinical trials, almost all 
(97–100%) of the patients completed ≥90% of the full 
duration of treatment (ie the patch was not removed 
early).36–40 In addition, it is difficult for patients to adjust 
their dose, whereas the authors have observed that those 
receiving oral medication frequently alter their own dose 
by taking a greater or fewer number of tablets than 
prescribed.
The capsaicin 179 mg patch is unlikely to have drug– 
drug interactions, and this means it is an appropriate 
candidate for combination therapy.39 The patch has been 
evaluated in 21 trials and all but one permitted concomi-
tant neuropathic pain medication, including non-steroidal 
anti-inflammatory drugs, antidepressants, analgesics, 
anticonvulsants, and anti-epileptics. No drug–drug interac-
tions were observed with any treatment and the capsaicin 
patch was well tolerated in combination. In a pooled ana-
lysis of four double-blind, controlled trials involving 
patients with PHN receiving at least one systemic neuro-
pathic pain medication (opioids, anticonvulsants, and non- 
SSRI antidepressants), the efficacy of the capsaicin patch 
was evident in terms of significantly greater reductions in 
NPRS scores compared with the control group, regardless 
of concomitant medication use.41 In those receiving the 
capsaicin patch versus control, respectively, reductions 
of –26.1% versus –18.1% (p=0.0011) were seen in those 
receiving systemic medications and –36.5% versus – 
26.2% (p=0.0002) in those not using systemic medica-
tions, during weeks 2 to 8.
Nevertheless, while the capsaicin 179 mg patch can be 
combined effectively and safely with systemic therapies, it 
may also contribute to a lower burden of therapy by 
allowing concomitant systemic therapy to be reduced or 
stopped. In the QUEPP study, a large non-interventional, 
real-world study in 1044 patients with non-diabetic PNP, 
a reduction in the use of long-term concomitant PNP 
medication was shown, particularly among those with 
a shorter duration of pre-existing pain.42 While over 73% 
of patients were receiving concomitant medications at 
baseline regardless of pain duration, 28% of those with 
pain for <6 months, 13.9% with pain for 6–24 months, 
6.8% with pain for >2–10 years, and 2% with pain for >10 
years discontinued concomitant medication.
Another aspect of treatment with the capsaicin patch 
that contributes to its reduced burden of treatment is the 
flexibility of the regimen and durability of response. It can 
be given based on individual patient need for a range of 
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PNP subtypes.34,35,43,44 For example, ASCEND—an open- 
label, non-interventional, real-world study in patients with 
non-diabetic PNP—showed that administration of the cap-
saicin patch can provide pain relief that is sustained over 
time and with subsequent treatments. The median time 
to second treatment was >26 weeks and increased to >43 
weeks from second to third treatment.35 In the QAPSA 
study—a longitudinal, non-interventional, real-world study 
conducted in France in 684 patients with non-diabetic 
PNP,43 patients were treated with up to five capsaicin 
179 mg patches. The interval between successive patch 
applications ranged from 3.7 months between first 
and second applications to 3.2 months between third and 
fourth applications. Furthermore, a meta-analysis of seven 
double-blind, controlled studies in 1313 patients with PHN 
and 801 patients with HIV-AN found that >90% of those 
who responded to treatment continued to respond beyond 
3 months and that the mean duration of response was >5 
months.44 Most long-term responders required just 1–3 
patch treatments within a year to maintain their response. 
In these long-term responders, this limited number of 
treatments may have considerable implications for patient 
convenience, adherence, and cost-effectiveness.
Duration of PNP and Effect on 
Response
There appears to be a correlation between a shorter time 
from diagnosis to initiation of therapy with the capsaicin 
179 mg patch and a better treatment response,35,42 as 
described below.
In the real-world QUEPP study, as described above, 1044 
patients with non-diabetic PNP received a single application 
of the capsaicin 179 mg patch and were followed for up to 12 
weeks.42,45 The mean duration of existing pain at baseline 
was 4.4 years and 9.4% of patients had suffered from pain for 
>10 years. The capsaicin 179 mg patch was associated with 
a consistent reduction in NPRS score versus baseline and, at 
week 12, 37.7% of patients experienced a ≥30% response 
and nearly a quarter (24.5%) achieved a ≥50% response. 
Changes in NPRS scores and responder rates were generally 
consistent across the different PNP subsets. When assessed 
according to the duration of pain reported at baseline, how-
ever, the greatest reduction (36.6%) was observed in those 
who had experienced pain for <6 months at baseline, com-
pared with those who had pain for >6 months (Table 2). In 
addition, the smallest reduction (19.2%) was observed in 
those who had pain for >10 years at baseline. Responder 
rates followed a similar trend: ≥30% and ≥50% responder 
rates of 61.7% and 39.3% were observed among those with 
<6 months of pain, compared with 32.3% and 14.1%, respec-
tively, in those with >10 years of pain.
The ASCEND trial investigated repeated applications 
of the capsaicin 179 mg patch over 52 weeks in 420 
patients with non-diabetic PNP.35 It demonstrated an over-
all reduction in NPRS average daily pain score of 26.6% 
(95% CI 23.6–29.6) from baseline to weeks 2 and 8. This 
reduction was sustained with repeated applications, 
regardless of PNP condition, providing an overall pain 
reduction of 37% (95% CI 31.3–42.7) at week 52. 
Consistent with QUEPP, in ASCEND, those with the 
shortest duration of pain experienced the highest pain 
response from baseline to weeks 2 and 8 compared with 
patients with longer durations of pain (Table 3). Moreover, 
a greater proportion were ≥30% responders after the first 
treatment in the group with the shortest duration of pain 
(62.4% vs 39.4%, 40.4%, and 35.9% in the 0.72–2.1-year, 
>2.1–5.4-year, and >5.4-year PNP duration quartiles, 
respectively). In addition, greater pain reductions were 
observed in those treated with the capsaicin 179 mg 
patch as a first- or second-line treatment, compared with 
Table 2 The Mean Changes of Pain Intensity Between 7 and 14 
Days and 12 Weeks versus Baseline According to the Duration 
of Pre-Existing Neuropathic Pain in QUEPP
Pain Duration n Mean Reduction % SEM
<6 months 105 36.6 4.6
6 months–2 years 311 25.1 1.9
>2 years–10 years 391 22.3 1.6
>10 years 99 19.2 2.6
No data 119 25.9 2.9
Total 1025 24.7 1.1
Abbreviation: SEM, standard error of mean.
Table 3 Reduction from Baseline to Weeks 2 and 8 in Mean 
NPRS Score According to PNP Duration in ASCEND
Quartile 
According to 
PNP Duration, 
Years
n Reduction from 
Baseline to Weeks 2 
and 8 in Mean NPRS 
Score, %
95% CI
0–0.72 101 36.3 30.0–42.6
0.72–2.1 104 23.6 17.1–30.1
>2.1–5.4 104 25.0 19.4–30.6
>5.4 103 21.8 16.4–27.2
Abbreviations: CI, confidence interval; NPRS, Numerical Pain Rating Scale; PNP, 
peripheral neuropathic pain.
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those in which it was at least a third-line treatment 
(changes in mean NPRS scores from baseline to weeks 2 
and 8 were –30.5% [n=80], –28.1% [n=177], and –22.8% 
[n=155], respectively). Together, QUEPP and ASCEND 
suggest a benefit of early initiation of the capsaicin 179 mg 
patch for optimal pain outcomes.
The observed benefit of early treatment is not well under-
stood. While a spontaneous healing process cannot be ruled 
out, it has been suggested that it may be possible to reverse 
some of the underlying pathophysiological and psychologi-
cal symptoms of PNP at an early stage of the condition, 
before the onset of chronicity.42 Given that this phenomenon 
is so evident with the capsaicin 179 mg patch, it has been 
hypothesized that it may be associated with the particular 
components of pain that the capsaicin patch acts upon. 
Nevertheless, the response rate does not seem to be related 
to underlying pathology, intensity of pain at baseline, or with 
the presence of allodynic or hyperalgesia.46
One possible explanation relates to the depletion of neu-
ropeptides, calcitonin gene-related peptide (which has a key 
role in pain signal transmission by potentiating nociceptive 
signaling) and substance P. After application of capsaicin, 
there is a release of these substances from the depots and, 
when depleted, the inflammatory cascade stops.47,48 
A further explanation considers that an interruption of per-
ipheral input with a rapidly acting topical treatment may stop 
central sensitization, disrupting the complex psychological 
factors that contribute to pain, pain memory, and chronifica-
tion. Clinical experience of the authors has shown that the 
onset of pain relief is slower with oral medication compared 
with topical therapy and it may be that, with oral medication, 
the cycle is not disrupted as quickly.
The phenomenon of the benefit of early therapy remains 
under investigation, and the authors note that in clinical 
practice, all patients who have been experiencing PNP for 
many years are refractory to multiple treatments; neverthe-
less, in our experience, patients with a long duration of PNP 
can benefit from treatment with the capsaicin 179 mg patch, 
possibly due to its distinct mechanism of action versus pre-
viously administered pharmacological therapies.
Other Determinants of Response to 
the Capsaicin 179 mg Patch
There have been several attempts to identify predictors 
of response to the capsaicin 179 mg patch. One study of 
57 patients found that responders had a lower quantita-
tive sensory testing (QST)-determined pressure pain 
threshold in the area of their PNP than non-responders, 
but both responders and non-responders experienced 
meaningful reductions in the size of the painful area 
following treatment.49 Another study of 20 patients 
found that the presence of cold and pinprick hyperalgesia 
was predictive of response.50 Research by the German 
Neuropathic Pain Research Network, EUROPAIN, and 
NEUROPAIN consortia suggests it may be possible to 
define clusters of patients according to QST, on the basis 
that those with different sensory profiles might exhibit 
different neurobiological mechanisms and therefore 
might respond differently to treatment.51 This approach 
warrants further investigation in treatment trials. 
However, QST is time-consuming and this may not be 
the most efficient way to identify responders. 
Quantitative thermal testing,52 efficacy of lidocaine pre- 
treatment, and high pre-treatment pain score variability53 
have also been suggested as predictive of response to the 
capsaicin 179 mg patch, but patterns of sensory symp-
toms as measured using the painDETECT questionnaire 
were not useful in this regard.54
Emerging data suggest that TRPV1 polymorphisms 
could be useful in determining responders.46 In a study 
of 38 patients treated with the capsaicin patch, the poly-
morphism T469I—related to increased TRPV1 function— 
was associated with a significantly lower value in the Pain 
Catastrophizing Scale55 and a non-significant but numeri-
cally greater reduction of pain, as measured using the 
Visual Analog Scale, than those without the 
polymorphism.46
Conclusions
The capsaicin 179 mg patch is an effective and well- 
tolerated option for the treatment of localized PNP. The 
fact that it is associated with a low rate of systemic side 
effects makes it an appropriate option for those unable to 
tolerate the systemic side effects of commonly used oral 
treatments, such as pregabalin. The capsaicin 179 mg 
patch is equally effective when administered alone or in 
combination with systemic neuropathic pain medications. 
Given its lack of drug–drug interactions and lack of daily 
pill burden, the capsaicin 179 mg patch is particularly 
suitable for use in combination therapy. Real-world studies 
show particular benefit of early intervention with the cap-
saicin 179 mg patch, ie within 6 months of the onset of 
PNP. This highlights the need for an efficient process of 
referral to pain specialists, diagnosis, and initiation of 
appropriate treatment.
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Pregabalin has demonstrated efficacy in the treatment 
of many PNP conditions, with benefits in terms of both 
pain reduction and sleep interference, and is recommended 
as the first-line option in many guidelines. Clinicians can 
be confident in their prescription of pregabalin given its 
manageable safety profile, lack of unexpected side effects, 
and drug–drug interactions.26 Particularly when PNP is not 
localized and an oral option is warranted, pregabalin is 
a rational first choice.
Expert Opinion
In our clinical experience, for localized PNP on the trunk 
or extremities, the capsaicin 179 mg patch works at the 
site of pain and is effective quickly, with limited or no side 
effects. It also appears to be more effective in the relief of 
burning pain than in lancinating pain. In addition, although 
studies with QST have not conclusively demonstrated 
a relationship between response and dynamic allodynia, 
in our experience, the capsaicin 179 mg patch is especially 
useful in patients with dynamic and static allodynia, as 
well as hyperalgesia.
Pregabalin is an effective treatment and is positioned as 
a first-line option in many guidelines. From a practical 
point of view, for localized PNP, it is logical to start with 
the capsaicin 179 mg patch, which is rapid-acting and does 
not impose a considerable burden of therapy, before mov-
ing on to an oral pharmacological treatment if the patch 
does not work. It is our opinion that in most cases of 
localized PNP, it is worth a trial of the capsaicin 179 mg 
patch, even if the patient is already receiving pregabalin. 
The patient can be treated with the capsaicin patch, while 
the pregabalin dose is reduced over time. At the point at 
which the pain returns, the patient can continue on the last 
effective dose of pregabalin. On the other hand, pregabalin 
is a more suitable option for facial pain or central neuro-
pathic pain, given that capsaicin 179 mg patch is contra-
indicated for use in the face/above the hairline and is not 
indicated for central neuropathic pain. Similarly, pregaba-
lin is the more suitable option if there are doubts about the 
vascularization of an area (eg a poorly vascularized dia-
betic foot) or if the skin is not intact.
At times, it has been noted that patients do not experi-
ence an effect of the capsaicin 179 mg patch until its effect 
wears off. As a result, the authors recommend that HCPs 
and patients evaluate the effect over at least 12 weeks 
before trying a different treatment. As discussed, benefit 
manifests itself in various ways, not necessarily linked to 
a change in pain measures. Therefore, it is important to 
also assess patient-reported outcome measures (eg PGIC), 
reduction of area of pain or reduction in concomitant 
medication use.
A further key consideration in maximizing the poten-
tial for response to the capsaicin 179 mg patch is ensuring 
the correct application of the patch at the appropriate 
location. Well-trained clinical staff are paramount to 
ensure the patch is unfolded, applied, and removed cor-
rectly. In addition, an accurate assessment of the treatment 
area by physicians is needed to optimally position the 
patch. Inadequate response to the capsaicin patch may be 
linked to the inability of the patient to describe the painful 
area and/or inexperience of the clinician in identifying the 
location or type of pain. The best way to identify the 
treatment area is to use a von Frey hair to stroke the skin 
and identify the painful area. Once marked, this is where 
the patch should be applied. Training in this technique is 
necessary to enhance the accuracy and efficacy of capsai-
cin patch treatment.
Anxiety among patients about the use of the capsaicin 
179 mg patch has been observed in clinical practice. It is 
the responsibility of the HCPs to address this by providing 
information on the AEs such as transient erythema. It is 
also key to remember that any approach to the treatment of 
PNP should be multimodal and that patient expectations 
should be managed. If a patient presents with a mixed pain 
condition with both nociceptive and neuropathic compo-
nents, they should expect to see only a change in the 
neuropathic component with a PNP treatment. Thus, com-
bination therapy is often warranted in such cases.
The treatment of PNP remains a challenge and the 
patient’s suffering is often high. In contrast to the treat-
ment of purely nociceptive pain, in the treatment of PNP, 
we see that a pharmacological approach alone is often not 
effective. Research shows that numbers needed to treat 
vary from 4 to >10.4 This variation is probably because 
different phenotypes are concealed under the term neuro-
pathic pain. As long as we are unable to make a distinction 
between different phenotypes and likelihood of response to 
various therapies, pharmacological therapy will continue 
to be somewhat a “trial and error” exercise. Currently, 
treatment algorithms based on benefit:risk considerations 
are key, but it is also important to reduce the variation in 
clinical practice and to generate real-world data on 
whether current treatment choices are effective. In the 
meantime, one straightforward approach to the manage-
ment of PNP is to first consider whether the pain is local 
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versus more generalized and, for localized PNP, local 
treatment is preferred.
Overall Conclusion
Current expert opinion suggests that localized PNP should 
preferably be treated with a local treatment. Capsaicin 
179 mg patch is a locally applied treatment that has 
been shown to be non-inferior in efficacy to the oral 
treatment pregabalin with a better systemic tolerability 
profile and lower patient burden. The greatest benefit 
from the capsaicin 179 mg patch can be derived when 
used early in the patient journey. Nevertheless, its benefit 
is sometimes not immediately obvious to patients as it 
may affect parameters other than pain scores, such as area 
of allodynia. It is advisable not to switch capsaicin 
179 mg patch rapidly for another (eg oral) treatment as 
the effect of the capsaicin 179 mg patch may increase with 
an increasing number of applications. Capsaicin 179 mg 
patch is an appropriate approved treatment for localized 
PNP with a well-understood benefit:risk profile and is 
a valuable additional treatment for localized neuropathic 
pain.
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